Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Journal of Endocrinological Investigation

Volumn 33, Issue 9, 2010, Pages 671-682

  Peri, A ^a   Pirozzi, N ^b   Parenti, G ^a   Festuccia, F ^b   Mene P ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antidiuretic hormone (ADH); Arginine vasopressin (AVP); Hyponatremia; Plasma osmolality; Syndrome of inappropriate ADH release (SIADH)

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ARGIPRESSIN; CARBAMAZEPINE; CHLORPROPAMIDE; CONIVAPTAN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; ETIRACETAM; FUROSEMIDE; HALOPERIDOL; HYDROCHLOROTHIAZIDE; LITHIUM; LIXIVAPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE; PLACEBO; QUINOLONE; SATAVAPTAN; SEROTONIN UPTAKE INHIBITOR; SODIUM; TOLVAPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; UREA; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ABSCESS; ACID BASE BALANCE; ASTHMA; BACTERIAL PNEUMONIA; CENTRAL PONTINE MYELINOLYSIS; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM CANCER; DIURESIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENCEPHALITIS; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HERPES VIRUS INFECTION; HORMONE STRUCTURE; HORMONE SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; HYPERVOLEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOURICEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; LYMPHOMA; MENINGITIS; MESOTHELIOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSCLE HYPOTONIA; NASOPHARYNX TUMOR; NEPHROTOXICITY; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PLASMA OSMOLALITY; PNEUMOTHORAX; POSTOPERATIVE COMPLICATION; PROLACTINOMA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALT INTAKE; SARCOIDOSIS; SARCOMA; SIDE EFFECT; SODIUM BALANCE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SODIUM URINE LEVEL; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TEMPORAL ARTERITIS; THIRST; THROMBOSIS; TOTAL BODY WATER; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UREMIA; URINE OSMOLALITY; URINE VOLUME; UROGENITAL TRACT CANCER; VIRUS PNEUMONIA; WALDENSTROEM MACROGLOBULINEMIA; WATER DEPRIVATION; XEROSTOMIA;

ALGORITHMS; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MODELS, BIOLOGICAL; NEUROPHYSINS; OSMOLAR CONCENTRATION; PROTEIN PRECURSORS; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 78751690075     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7290     Document Type: Review

References (111)

1. O'Donoghue D, Trehan. SIADH and hyponatremia: foreword. NDT Plus 2009, 2 (Suppl 3): 1-4.
2. Hannon M, Thompson C. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol 2010, 162: S5-12.
3. Fall PJ. Hyponatremia and hypernatremia. A systematic approach to causes and their correction. Postgrad Med 2000, 107: 75-82.
4. Anderson RJ. Hospital-associated hyponatremia. Kidney Int 1986, 29: 1237-47.
5. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006, 119: 71e1-8.
6. Rabenou RA. Hyponatremia: disorder of water, not salt. J Cardiovasc Electrophysiol 2009, 20: E66.
7. Decaux G. The syndrome of inappropiate secretion of antidiuretic hormone (SIADH). Semin Nephrol 2009, 29: 239-56.
8. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007, 356: 2064-72.
9. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med 2000, 342: 1493-9.
10. rd ed.). Berlin: Springer, 2006. 573-607.
11. Elphick MR. NG peptides: a novel family of neurophysin-associated neuropeptides. Gene 2010, 458: 20-6.
12. Peters HP, Robben JH, Deen PM, Wetzeis JF. Water in healh and disease: new aspects of disturbances in water metabolism. Neth J Med 2007, 65: 325-32.
13. Maybauer MO, Maubauer DM, Enkhbaatar P, Traber DL. Physiology of vasopressin receptor. Best Pract Res Clin Anaesthesiol 2008, 22: 253-63.
14. Valenti G, Procino G, Tamma G, Carmosino M, Svelto M. Mini-review: aquaporin 2 trafficking. Endocrinology 2005, 146: 5063-70.
15. Verkman AS, Mitra AK. Structure and function of aquaporin water channels. Am J Physiol 2000, 278: F13-28.
16. Nedvetsky Pl, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol 2009, 190: 133-57.
17. Verkman AS, Mitra AK. Structure and function of aquaporin water channels. Am J Physiol 2000, 278: F13-28.
18. Schrier RW. Aquaporin-related disorders of water homeostasis. Drug News Perspect 2007, 20: 447-53.
19. Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. Nat Rev Nephrol 2010, 6: 168-78.
20. Ohbuchi T, Yokoyama T, Saito T, et al. Brain-derived neurotrophic factor inhibits spontaneous inhibitory postsynaptic currents in the rat supraoptic nucleus. Brain Res 2009, 1258: 34-42.
21. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006, 17: 1820-32.
22. Robertson GL. Regulation of arginine vasopressin in the syndrome inappropriate antediuresis. Am J Med 2006, 119 (Suppl 1): S36-42.
23. Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006, 119: S47-53.
24. Verbalis JG. An experimental model of syndrome of inappropriate antidiuretic hormone secretion in the rat. Am J Physiol 1984, 247: E540-53.
25. Papadimitriou A, Priftis KN. Regulation of hypotalamic-pituitary-adrenal axis. Neuroimmunomodulation 2009, 16: 265-71.
26. Kahn T. Reset osmostat and salt and water retention in the course of severe hyponatremia. Medicine (Baltimore) 2003, 82: 170-6.
27. Gerstberger R, Müller AR, Simon-Oppermann C. Functional hypothalamic angiotensin II and catecholamine receptor systems inside and outside the blood-brain barrier. Prog Brain Res 1992, 91: 423-33.
28. Feldman BJ, Rosenthal SM, Vargas GA. Nephrogenic syndrome of inappropriate antidiuresis. New Engl J Med 2005, 352: 1884-90.
29. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007, 18: 606-12.
30. Kramer DS, Drake ME Jr. Acute psychosis, polydipsia, and inappropriate secretion of antidiuretic hormone. Am J Med 1983, 75: 712-4.
31. Goldman MB, Luchins DJ, Robertson GL. Mechanisms of altered water metabolism in psycotic patients with polyuria and hyponatremia. N Engl J Med 1988, 318: 397-403.
32. Samaan Z, Macqueen G. Subacute alteration in level of consciousness in a woman with psychotic depression. J Psychiatry Neurosci 2008, 33: 280.
33. Dundas B, Harris M, Narasimhan M. Psychogenic polydipsia review: etiology, differential and treatment. Curr Psychiatry Rep 2007, 9: 236-41. (Pubitemid 46895102)
34. Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 1979, 44: 896-8.
35. Bressler RB, Huston DP. Water intoxication following moderate dose intravenous cyclophosphamide. Arch Intern Med 1985, 145: 548-9.
36. Bjorck E, Samuelsson J. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) after treatment with cyclophosphamide, alfa-interferon and betamethasone in in patient with multiple myeloma. Eur J Haematol 1996, 56: 323-5.
37. Jayachandran NV, Chandrasekhara PK, Thomas J, Agrawal S, Narsimulu G. Cyclophosphamide-associated complication: we need to be aware of SIADH and central pontine myelinolysis. Rheumatology 2009, 48: 89-90.
38. Koide T, Wakabayashi T, Matsuda T, Horiike S, Watanabe K. Hyponatremia associated with paroxetine induced by sodium-restricted diet and hypotonic saline. Pharm World Sci 2010, 32: 19-21.
39. Meulendijks D, Mannesse CK, Jansen PA, van Marum RJ, Egberts TC. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010, 33: 101-14.
40. Reddy P, Mooradian AD. Diagnosis and management of hyponatremia in hospitalised patients. Int J Clin Pract 2009, 64: 1494-508.
41. Kadowaki T, Hagura R, Kajinuma H, Kuzuya N, Yoshida S. Chlorpropamide-induced hyponatremia: incidence and risk factors. Diabetes Care 1983, 6: 468-71.
42. Welch WJ, Ott CE, Lorenz JN, Kotchen TA. Effects of chlorpropamide on loop of Henle function and plasma renin. Kidney Int 1986, 30: 712-6.
43. Kusano E, Braun-Werness JL, Vick DJ, Keller MJ, Dousa TP. Chlorpropamide action on renal concentrating mechanism in rats with hypothalamic diabetes insipidus. J Clin Invest 1983, 72: 1298-313.
44. Zalin AM, Hutchinson CE, Jong M, Matthews K. Hyponatraemia during treatment with chlorpropamide and Moduretic (amiloride plus hydrochlorothiazide) . Br Med J 1984, 289: 659.
45. Breyer MD, Breyer RM. Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 2000, 279: F12-23.
46. Szatalowicz VL, Goldberg JP, Anderson RJ. Plasma antidiuretic hormone in acute respiratory failure. Am J Med 1982, 72: 583-7.
47. Hill AR, Uribarri J, Mann J, Berl T. Altered water metabolism in tuberculosis: role of vasopressin. Am J Med 1990, 88: 357-64.
48. Lee P, Ho KK. Hyponatremia in pulmonary TB: evidence of ectopic antidiuretic hormone production. Chest 2010, 137: 207-8.
49. Braden GL, Mikolich DJ, White CF, Germain MJ, Fitzgibbons JP. Syndrome of inappropriate antidiuresis in Waldenstrom's macroglobulinemia. Am J Med 1986, 80: 1242-4.
50. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 2000, 8: 192-7.
51. Yamaji T, Ishibashi M, Hori T. Propressophysin in human blood: a possible marker of ectopic vasopressin production. J Clin Endocrinol Metab 1984, 59: 505-12.
52. Osterman J, Calhoun A, Dunham M, et al. Chronic syndrome of inappropriate antidiuretic hormone secretion and hypertension in a patient with olfactory neuroblastoma. Evidence of ectopic production of arginine vasopressin by the tumor. Arch Intern Med 1986, 146: 1731-5.
53. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000, 27: 322-34.
54. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer 2000, 8: 192-7.
55. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113: 5-21.
56. Lin M, Liu SJ, Lim IT. Disorders of water imbalance. Emerg Med Clin North Am 2005, 23: 749-70.
57. Fall PJ. Hyponatremia and hypematremia. A systematic approach to causes and their correction. Postgrad Med 2000, 107: 75-82.
58. Baylis PH. The syndrome of inappropiate antiuretic hormone secretion. Int J Biochem Cell Biol 2003, 35: 1495-9.
59. Chan TY. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management. Drugs Aging 1997, 11: 27-44.
60. Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol 2009, 29: 227-38.
61. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol 2008, 3: 1175-84.
62. Holm EA, Bie P, Ottesen M, Ødum L, Jespersen B. Diagnosis of the syndrome of inappropriate secretion of antidiuretic hormone. South Med J 2009, 102: 380-4.
63. Biswas M, Davies JS. Hyponatremia in clinical practice. Postgrad Med J 2007, 83: 373-8.
64. Passeron A, Dupeux S, Blanchard A. Hyponatremia: from physiopathology to practice. Rev Med Interne 2010, 31: 277-86.
65. Siragy HM. Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropiate antidiuretic hormone secretion: diagnosis and treatment options. Endocr Pract 2006, 12: 446-57.
66. Cogan E, Debieve MF, Pepersack T, Abramow M. Natriuresis and atrial natriuretic factor secretion during inappropriate antidiuresis. Am J Med 1988, 84: 409-18.
67. Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting? Kidney Int 2009, 76: 934-8.
68. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998, 32: 917-33.
69. Akalin E, Chandrakantan A, Keane J, Hamburger RJ. Normouricemia in the syndrome of inappropriate antidiuretic hormone secretion. Am J Kidney Dis 2001, 37: E8.
70. Fenske W, Störk S, Koschker AC, et al. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab 2008, 93: 2991-7.
71. Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990, 37: 1006-8.
72. Arieff AI. Hyponatremia, convulsion, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986, 314: 1529-35.
73. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Int Med 1997, 126: 57-62.
74. Stems RH, Thomas DJ, Herndon RM. Brain dehydration and neurologic deterioration after correction of hyponatremia. Kidney Int 1989, 35: 69-75.
75. Sterns RH. The treatment of hyponatremia: first, do no harm. Am J Med 1990, 88: 557-60.
76. Verbalis JG, Martinez AJ. Neurological and neurophatological sequelae of correction of chronic hyponatremia. Kidney Int 1991, 39: 1274-82.
77. Parenti G, Ricca V, Zogheri A, Serio M, Mannelli M, Peri A. A case of hyponatremia caused by central hypocortisolism. Nat Clin Pract Endocrinol Metab 2007, 4: 369-75.
78. Reynolds RM, Seckl JR. Hyponatraemia for the clinical endocrinologists. Clin Endocrinol 2005, 63: 366-74.
79. Thompson CJ, Sherlock M. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol 2010, 162 (Suppl 1): S13-8.
80. st ed. New York: McGraw-Hill. 1986, 338-85.
81. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007, 120 (Suppl 1): S1-21.
82. Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 2004, 287: E1019-23.
83. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci 2008, 105: 3634-9.
84. Baylis PH, Heath DA. Water disturbances in patients treated with oral lithium carbonate. Ann Int Med 1978, 88: 607-9.
85. Walker RG, Escott M, Birchall I, Dowling JP, Kincaid-Smith P. Chronic progressive renal lesions induced by lithium. Kidney Int 1986, 29: 875-81.
86. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009, 5: 270-6.
87. Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. Br Med J (Clin Res Ed) 1985, 290: 1782-3.
88. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001, 110: 582-4.
89. Soupart A, Schroeder B, Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrol Dial Transplant 2007, 22: 1856-63.
90. Van Reeth O, Decaux G. Rapid correction of hyponatraemia with urea may protect against brain damage in rats. Clin Sci 1989, 77: 351-5.
91. Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982, 72: 339-53.
92. Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003, 14: 182-7.
93. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994, 4: 1522-30.
94. Gross P. Treatment of severe hyponatremia. Kidney Int 2001, 60: 2417-27.
95. Martin PY, Abraham WT, Lieming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999, 10: 2165-70.
96. Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol 2005, 2: 14B-23B
97. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1 A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104: 2417-23.
98. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006, 91: 2145-52.
99. Decaux G. Treatment of hyponatremic encephalopathy. J Lab Clin Med 2001, 138: 403.
100. Gerbes AL, Gülberg V, Ginès P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124: 933-9.
101. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006, 47: 1615-21.
102. Biogen Idek and Cardiokine Partner to Develop Lixivaptan, a Novel Vasopressin Antagonist. 2007. Available at: http:/www.reuters.com/artide/ pressRelease/idUS162428+14-Feb-2008+BW20080214.
103. Soupart A, Gross P, Legros JJ, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006, 1: 1154-60.
104. Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008, 48: 204-13.
105. Gheorghiade M, Gottlieb SS, Udelson JE, et al; Tolvaptan Investigators. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006, 97: 1064-7.
106. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007, 50: 213-22.
107. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral Vasopressin V2-receptor antagonist, for hyponatremia. N Eng J Med 2006, 355: 2099-112.
108. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297: 1319-31.
109. Berl T, Quittnat-Pelletier F, Verbalis JG, et al; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010, 21: 705-12.
110. Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis 2010, 56: 325-37.
111. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010, 25: 554-63.